Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1987 1
1988 1
1991 1
1992 2
1996 1
1997 2
1999 1
2001 1
2002 1
2003 4
2004 3
2005 1
2006 4
2007 4
2008 5
2009 6
2010 6
2011 7
2012 11
2013 8
2014 24
2015 20
2016 22
2017 14
2018 9
2019 13
2020 3
Text availability
Article attribute
Article type
Publication date

Similar Articles for PMID: 25349205

148 results
Results by year
Filters applied: . Clear all
Page 1
Randomized Placebo-Controlled EPPIC Trials of AST-120 in CKD.
Schulman G, Berl T, Beck GJ, Remuzzi G, Ritz E, Arita K, Kato A, Shimizu M. Schulman G, et al. J Am Soc Nephrol. 2015 Jul;26(7):1732-46. doi: 10.1681/ASN.2014010042. Epub 2014 Oct 27. J Am Soc Nephrol. 2015. PMID: 25349205 Free PMC article. Clinical Trial.
Risk factors for progression of chronic kidney disease in the EPPIC trials and the effect of AST-120.
Schulman G, Berl T, Beck GJ, Remuzzi G, Ritz E, Shimizu M, Kikuchi M, Shobu Y. Schulman G, et al. Clin Exp Nephrol. 2018 Apr;22(2):299-308. doi: 10.1007/s10157-017-1447-0. Epub 2017 Jul 24. Clin Exp Nephrol. 2018. PMID: 28741050 Free PMC article. Clinical Trial.
The effects of AST-120 on chronic kidney disease progression in the United States of America: a post hoc subgroup analysis of randomized controlled trials.
Schulman G, Berl T, Beck GJ, Remuzzi G, Ritz E, Shimizu M, Shobu Y, Kikuchi M. Schulman G, et al. BMC Nephrol. 2016 Sep 30;17(1):141. doi: 10.1186/s12882-016-0357-9. BMC Nephrol. 2016. PMID: 27716149 Free PMC article. Clinical Trial.
Review of the efficacy of AST-120 (KREMEZIN®) on renal function in chronic kidney disease patients.
Asai M, Kumakura S, Kikuchi M. Asai M, et al. Ren Fail. 2019 Nov;41(1):47-56. doi: 10.1080/0886022X.2018.1561376. Ren Fail. 2019. PMID: 30732506 Free PMC article. Review.
Beneficial effects of Fu-Zheng-Qu-Zhuo oral liquid combined with standard integrated therapy in patients with chronic kidney disease (stage 3-4): A randomized placebo-controlled clinical trial.
Li S, Rao XR, Dai XW, Pei K, Wang L, Huo BM, Wang XJ, Kong LX, Zhang NN, Lian FM. Li S, et al. Medicine (Baltimore). 2017 Jul;96(28):e7448. doi: 10.1097/MD.0000000000007448. Medicine (Baltimore). 2017. PMID: 28700482 Free PMC article. Clinical Trial.
Febuxostat Therapy for Patients With Stage 3 CKD and Asymptomatic Hyperuricemia: A Randomized Trial.
Kimura K, Hosoya T, Uchida S, Inaba M, Makino H, Maruyama S, Ito S, Yamamoto T, Tomino Y, Ohno I, Shibagaki Y, Iimuro S, Imai N, Kuwabara M, Hayakawa H, Ohtsu H, Ohashi Y; FEATHER Study Investigators. Kimura K, et al. Am J Kidney Dis. 2018 Dec;72(6):798-810. doi: 10.1053/j.ajkd.2018.06.028. Epub 2018 Sep 1. Am J Kidney Dis. 2018. PMID: 30177485 Free article. Clinical Trial.
Effect of a carbonaceous oral adsorbent on the progression of CKD: a multicenter, randomized, controlled trial.
Akizawa T, Asano Y, Morita S, Wakita T, Onishi Y, Fukuhara S, Gejyo F, Matsuo S, Yorioka N, Kurokawa K; CAP-KD Study Group. Akizawa T, et al. Am J Kidney Dis. 2009 Sep;54(3):459-67. doi: 10.1053/j.ajkd.2009.05.011. Epub 2009 Jul 17. Am J Kidney Dis. 2009. PMID: 19615804 Clinical Trial.
A multicenter, randomized, double-blind, placebo-controlled, dose-ranging study of AST-120 (Kremezin) in patients with moderate to severe CKD.
Schulman G, Agarwal R, Acharya M, Berl T, Blumenthal S, Kopyt N. Schulman G, et al. Am J Kidney Dis. 2006 Apr;47(4):565-77. doi: 10.1053/j.ajkd.2005.12.036. Am J Kidney Dis. 2006. PMID: 16564934 Clinical Trial.
Effect of hemoglobin target on progression of kidney disease: a secondary analysis of the CHOIR (Correction of Hemoglobin and Outcomes in Renal Insufficiency) trial.
Inrig JK, Barnhart HX, Reddan D, Patel UD, Sapp S, Califf RM, Singh AK, Szczech LA. Inrig JK, et al. Am J Kidney Dis. 2012 Sep;60(3):390-401. doi: 10.1053/j.ajkd.2012.03.009. Epub 2012 Apr 25. Am J Kidney Dis. 2012. PMID: 22537421 Free PMC article. Clinical Trial.
Effect of repeated oral administrations of the oral adsorbent AST-120 on serum creatinine and other markers of renal function. A randomized controlled study in patients with chronic kidney disease.
Marier JF, Lee J, Kambhampati SR, Galitz L, Vargas R, Moberly J, Salazar DE. Marier JF, et al. Am J Nephrol. 2006;26(2):136-41. doi: 10.1159/000092242. Epub 2006 Mar 22. Am J Nephrol. 2006. PMID: 16549905 Clinical Trial.
148 results
Jump to page
Feedback